Oral News and Research

RSS

Water Pik launches advertising campaign to introduce consumers to new Waterpik Water Flosser

Water Pik, Inc., a leading developer and manufacturer of innovative personal healthcare products, today announced the launch of the "Say No To String" advertising campaign to introduce consumers to the new Waterpik Water Flosser and to promote it as an easier and more effective alternative to traditional string floss.

28 Jul 2010

Pharmasset announces data from PSI-352938 single ascending dose study

Pharmasset, Inc. announced today that safety and pharmacokinetic data from the PSI-352938 single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.

28 Jul 2010

Experts to discuss treatment options for wounded warriors at USU-HJF Military Medicine Symposium

The USU-HJF Military Medicine Symposium will gather prominent civilian and military researchers and clinicians from across the United States to discuss current research and identify opportunities to collaborate and share information that could speed treatments to wounded warriors. The symposium also will bring together a broad spectrum of participants from military health leadership, federal agencies and private research institutions to philanthropists and charitable foundations, representatives of industry, and policymakers.

28 Jul 2010

FDA accepts for filing Cladribine Tablets NDA for MS

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

28 Jul 2010

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.

28 Jul 2010

Medicare to bundle payments for end-stage renal care, reward quality

Medicare payment for end-stage renal disease care may soon be tied to performance and quality measures if a new proposed rule issued by the Centers for Medicare and Medicaid Services is finalized. "If the rule is finalized, ESRD providers that do not meet set standards" - two measures for anemia management and one for hemodialysis quality - "could have their Medicare payments lowered by up to 2 percent starting January 2012, the CMS said" (McKinney, 7/26).

28 Jul 2010

InterMune second-quarter total revenue decreases to $5.9 million

InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2010. InterMune also highlighted its recent clinical development and business activities, and provided forward-looking financial guidance for 2010.

28 Jul 2010

New specially designed operatory for Oral Surgery, IV Sedation Dentistry

Union Dental Holdings, Inc. - http://www.uniondental.com - a provider of multi-state dental services for union members, is pleased to announce that it has built a specially designed operatory to perform Oral Surgery and IV Sedation Dentistry. This opens a completely new element of dentistry because there are a tremendous amount of patients who require the sedation in order to perform these procedures.

27 Jul 2010

Data shows Exergen temporal artery thermometer outsells all other brands

The Exergen temporal artery thermometer outsells all other brands at retailers nationwide that stock the Exergen TemporalScanner, according to data compiled by leading market research firms. In comparing sales of all types of thermometers, including national brands and private label products, Nielsen and Information Resources Inc. found Exergen came out on top.

27 Jul 2010

Researchers reveal biological rationale for why corticosteroids help people with lupus

Researchers at UT Southwestern Medical Center have uncovered the biological rationale for why large doses of corticosteroids given repeatedly over several weeks may help individuals with lupus, a chronic inflammatory disease that affects more than 1 million people in the U.S.

27 Jul 2010

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

The Singaporean government's emphasis on raising awareness on the benefit of frequent health check-ups have significantly raised the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have a challenging task ahead for improving treatment for this market as current treatment requires high dosage frequency, but potentially has serious side effects.

27 Jul 2010

Ampio finalizes negotiations to acquire DMI BioSciences

Ampio Pharmaceuticals, Inc. today announced it has finalized negotiations with the directors of DMI BioSciences, Inc. (DMI) to acquire DMI BioSciences, Inc. This acquisition will give Ampio access to all rights, royalties and patents associated with DMI's major assets, drugs for male sexual dysfunction including premature ejaculation (PE) and combination drugs to treat premature ejaculation and erectile dysfunction (ED).

27 Jul 2010

NIH awards BU $1.6M grant to target protein-protein interactions with synthetic organic drugs

An interdisciplinary team of Boston University professors is launching a project to develop new ways to target protein-protein interactions with synthetic organic drugs. Financed by a four-year $1.6 million grant from the National Institutes of Health, the goal is to develop new approaches for discovering "drug-like" small molecule inhibitors against challenging protein-protein interaction (PPI) interfaces.

27 Jul 2010

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.

27 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

Colorcon acquires business of Pharmaceutical Coatings

Colorcon, Inc. today announced the acquisition of the business of Pharmaceutical Coatings Pvt. Ltd. (India) which includes the company's full product portfolio, plus a new facility in Goa that is currently under construction.

26 Jul 2010

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.

26 Jul 2010

Experimental treatment for sickle cell disease enters Phase 3 clinical trials

An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO announced today.

26 Jul 2010

Control of cell migration gene can reduce spread of oral cancer cells: Study

The spread of cancer cells in the tongue may be reduced if a gene that regulates cancer cell migration can be controlled, according to new research at the University of Illinois at Chicago.

26 Jul 2010

Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin

Unigene Laboratories, Inc. today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa's oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.

23 Jul 2010

Oral News and Research

Water Pik launches advertising campaign to introduce consumers to new Waterpik Water Flosser

Pharmasset announces data from PSI-352938 single ascending dose study

Experts to discuss treatment options for wounded warriors at USU-HJF Military Medicine Symposium

FDA accepts for filing Cladribine Tablets NDA for MS

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Medicare to bundle payments for end-stage renal care, reward quality

InterMune second-quarter total revenue decreases to $5.9 million

New specially designed operatory for Oral Surgery, IV Sedation Dentistry

Data shows Exergen temporal artery thermometer outsells all other brands

Researchers reveal biological rationale for why corticosteroids help people with lupus

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

Ampio finalizes negotiations to acquire DMI BioSciences

NIH awards BU $1.6M grant to target protein-protein interactions with synthetic organic drugs

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Colorcon acquires business of Pharmaceutical Coatings

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Experimental treatment for sickle cell disease enters Phase 3 clinical trials

Control of cell migration gene can reduce spread of oral cancer cells: Study

Tarsa Therapeutics completes patient enrollment in Phase III ORACAL trial of oral calcitonin

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News